🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

42 results for “LIGAND” Clear

  1. Intravenous Carbamazepine (IV CBZ)

    LIGAND PHARMACEUTICALS INC

    Epilepsy

    phase 3 small molecule completed

    1 trial

  2. Targretin Gel 1%

    LIGAND PHARMACEUTICALS INC

    Alopecia Areata

    phase 3 small molecule completed

    1 trial

  3. lasofoxifene

    LIGAND PHARMACEUTICALS INC

    Osteoporosis

    phase 3 small molecule completed

    3 trials

  4. ziltivekimab, Ziltivekimab

    Novo Nordisk A/S

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    phase 3 small molecule active

    1 trial

  5. -, ABIRATERONE, DEGARELIX, RELUGOLIX, APALUTAMIDE, ABIRATERONE, ENZALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, AAA802, AAA502, Locametz 25 micrograms kit for radiopharmaceutical preparation, DEGARELIX ACETATE, DAROLUTAMIDE

    Novartis Ophthalmics Europe

    PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.

    phase 2 small molecule active

    1 trial

  6. A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastatic neuroendocrine prostate cancer

    Novartis Ophthalmics Europe

    Metastatic neuroendocrine prostate cancer

    phase 2 other active

    1 trial

  7. Alitretinoin

    LIGAND PHARMACEUTICALS INC

    Sarcoma, Kaposi

    phase 2 small molecule completed

    2 trials

  8. Aplindore

    LIGAND PHARMACEUTICALS INC

    Early Stage Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  9. Aplindore

    LIGAND PHARMACEUTICALS INC

    Restless Legs Syndrome

    phase 2 small molecule completed

    1 trial

  10. Bexarotene

    LIGAND PHARMACEUTICALS INC

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  11. Bexarotene

    LIGAND PHARMACEUTICALS INC

    Sarcoma, Kaposi

    phase 2 small molecule completed

    1 trial

  12. Bexarotene (targretin)

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule terminated

    1 trial

  13. Bexarotene 1% gel

    LIGAND PHARMACEUTICALS INC

    Parapsoriasis

    phase 2 small molecule terminated

    1 trial

  14. Bexarotene/NBUVB vs placebo NBUVB

    LIGAND PHARMACEUTICALS INC

    Psoriasis

    phase 2 small molecule completed

    1 trial

  15. Budesonide

    LIGAND PHARMACEUTICALS INC

    Seasonal Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  16. Budesonide + Azelastine

    LIGAND PHARMACEUTICALS INC

    Seasonal Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  17. CE-Iohexol

    LIGAND PHARMACEUTICALS INC

    Contrast-induced Nephropathy

    phase 2 small molecule terminated

    1 trial

  18. Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells

    First Tracks Biotherapeutics

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  19. LGD-6972-5 mg

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  20. Lasofoxifene

    LIGAND PHARMACEUTICALS INC

    Bone Loss

    phase 2 small molecule completed

    1 trial

  21. MB07133 300mg/m2/day

    LIGAND PHARMACEUTICALS INC

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  22. MB07803

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  23. MB07811

    LIGAND PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  24. PS433540

    LIGAND PHARMACEUTICALS INC

    Hypertension

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources